Corbus Pharmaceuticals Holdings, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2024 - Q4(Jul 24 · Aug 24 · Sep 24)
Total Assets
$168M
↑+7.9% +$12Mvs FY2024
Total Liabilities
$21M
↑+75.1% +$9Mvs FY2024
Equity
$148M
↑+3.6% +$5Mvs FY2024
Cash
$28M
↑+65.7% +$11Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $168M | $156M |
| Current Assets | $167M | $153M |
| Cash | $28M | $17M |
| ST Investments | $135M | $132M |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $4M | $4M |
| Non-Current Assets | $1M | $3M |
| PPE | $159K | $385K |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $1M | $3M |
| Total Liab+Eq | $168M | $156M |
| Current Liab. | $21M | $12M |
| Accounts Payable | $2M | $5M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $18M | $7M |
| Non-Current Liab. | $0 | $2M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $0 | $2M |
| Equity | $148M | $142M |
| Retained Earnings | $555M | $477M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · CRBP · Comparing FY2025 vs FY2024